ZA200107689B - 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders. - Google Patents

1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.

Info

Publication number
ZA200107689B
ZA200107689B ZA200107689A ZA200107689A ZA200107689B ZA 200107689 B ZA200107689 B ZA 200107689B ZA 200107689 A ZA200107689 A ZA 200107689A ZA 200107689 A ZA200107689 A ZA 200107689A ZA 200107689 B ZA200107689 B ZA 200107689B
Authority
ZA
South Africa
Prior art keywords
arenesulfonyl
pyrrolidine
aryl
treatment
cns disorders
Prior art date
Application number
ZA200107689A
Other languages
English (en)
Inventor
Vincent Mutel
Juergen Wichmann
Eric Vieira
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200107689B publication Critical patent/ZA200107689B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
ZA200107689A 1999-03-25 2001-09-18 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders. ZA200107689B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99106004 1999-03-25

Publications (1)

Publication Number Publication Date
ZA200107689B true ZA200107689B (en) 2002-12-18

Family

ID=8237852

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200107689A ZA200107689B (en) 1999-03-25 2001-09-18 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.

Country Status (34)

Country Link
US (1) US6284785B1 (fr)
EP (1) EP1165510B1 (fr)
JP (1) JP3590589B2 (fr)
KR (1) KR100452648B1 (fr)
CN (1) CN1150165C (fr)
AR (1) AR028817A1 (fr)
AT (1) ATE305451T1 (fr)
AU (1) AU765212B2 (fr)
BR (1) BR0009278A (fr)
CA (1) CA2368418C (fr)
CO (1) CO5050296A1 (fr)
CZ (1) CZ20013402A3 (fr)
DE (1) DE60022867T2 (fr)
DK (1) DK1165510T3 (fr)
ES (1) ES2249249T3 (fr)
HK (1) HK1044944B (fr)
HR (1) HRP20010682A2 (fr)
HU (1) HUP0200284A3 (fr)
IL (1) IL145301A0 (fr)
JO (1) JO2274B1 (fr)
MA (1) MA26779A1 (fr)
MX (1) MXPA01009623A (fr)
MY (1) MY125295A (fr)
NO (1) NO319948B1 (fr)
NZ (1) NZ514037A (fr)
PE (1) PE20001583A1 (fr)
PL (1) PL204436B1 (fr)
RU (1) RU2248350C2 (fr)
SI (1) SI1165510T1 (fr)
TR (1) TR200102789T2 (fr)
TW (1) TW575561B (fr)
WO (1) WO2000058285A1 (fr)
YU (1) YU67601A (fr)
ZA (1) ZA200107689B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589978B2 (en) 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US20040267010A1 (en) * 2001-02-02 2004-12-30 Forbes Ian Thomson Sulfonamide compounds, their preparation and use
TW200302717A (en) * 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
WO2005030128A2 (fr) * 2003-09-23 2005-04-07 Merck & Co., Inc. Modulateurs pyrazole de recepteurs de glutamate metabotropiques
JP2007538106A (ja) * 2004-05-20 2007-12-27 イーラン ファーマスーティカルズ、インコーポレイテッド γセクレターゼのＮ−環式スルホンアミド阻害剤
US8048909B2 (en) 2004-09-30 2011-11-01 Takeda Pharmaceutical Company Limited Proton pump inhibitors
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
EP2275095A3 (fr) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
ES2391757T3 (es) 2005-08-30 2012-11-29 Akeda Pharmaceutical Company Limited Derivados de 1-H-pirrol sustituidos con 1-heterociclilsulfonilo, 2-aminometilo, 5-heteroarilo como inhibidores de la secreción de ácido
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
JO2871B1 (en) 2008-08-27 2015-03-15 تاكيدا فارماسوتيكال كمبني ليمتد Perol compounds
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
US10603313B2 (en) 2017-07-31 2020-03-31 Chiromics, LLC Allosteric modulators of the mu opioid receptor
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2685325B1 (fr) * 1991-12-20 1994-02-04 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9612884D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
HK1044944B (zh) 2004-10-21
WO2000058285A1 (fr) 2000-10-05
NO20014617D0 (no) 2001-09-24
US6284785B1 (en) 2001-09-04
CZ20013402A3 (cs) 2002-03-13
HK1044944A1 (en) 2002-11-08
RU2248350C2 (ru) 2005-03-20
EP1165510B1 (fr) 2005-09-28
MA26779A1 (fr) 2004-12-20
KR20010108403A (ko) 2001-12-07
ATE305451T1 (de) 2005-10-15
AU765212B2 (en) 2003-09-11
CN1150165C (zh) 2004-05-19
NZ514037A (en) 2004-01-30
PL350679A1 (en) 2003-01-27
HUP0200284A3 (en) 2003-04-28
IL145301A0 (en) 2002-06-30
HRP20010682A2 (en) 2002-10-31
TW575561B (en) 2004-02-11
JO2274B1 (en) 2005-04-07
NO20014617L (no) 2001-09-24
YU67601A (sh) 2004-09-03
DE60022867T2 (de) 2006-06-22
CA2368418C (fr) 2009-03-10
CO5050296A1 (es) 2001-06-27
SI1165510T1 (sl) 2005-12-31
JP3590589B2 (ja) 2004-11-17
AR028817A1 (es) 2003-05-28
ES2249249T3 (es) 2006-04-01
DE60022867D1 (de) 2006-02-09
TR200102789T2 (tr) 2002-04-22
MY125295A (en) 2006-07-31
NO319948B1 (no) 2005-10-03
PL204436B1 (pl) 2010-01-29
KR100452648B1 (ko) 2004-10-12
JP2002540191A (ja) 2002-11-26
CA2368418A1 (fr) 2000-10-05
CN1345311A (zh) 2002-04-17
PE20001583A1 (es) 2001-01-15
MXPA01009623A (es) 2002-05-06
AU3291500A (en) 2000-10-16
BR0009278A (pt) 2001-12-26
DK1165510T3 (da) 2006-02-06
EP1165510A1 (fr) 2002-01-02
HUP0200284A2 (en) 2002-06-29

Similar Documents

Publication Publication Date Title
ZA200107689B (en) 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.
HK1047284A1 (en) 2-amino-benzoxazinone derivatives for the treatment of obesity
ZA200109073B (en) Compositions for treatment of disorders of the oesophagus.
HK1052647A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
HUP0400914A3 (en) Methods of treatment of mitochondrial disorders
IL143979A0 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
IL153425A0 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
AU5309400A (en) Methods and compositions for the treatment of neuroleptic and related disorders using sertindole derivatives
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AU6910600A (en) Methods for the treatment of mental disorders
AU5908300A (en) Prevention and treatment of amyloid-associated disorders
AU2002215047A1 (en) Isoquinoline derivatives useful in the treatment of cns disorders
AU7388101A (en) Indole derivatives useful for the treatment of cns disorders
EP1181308A4 (fr) Methodes de traitement de demence neuronale associee a une atrophie
PL347976A1 (en) Isonipecotamides for the treatment of integrin−mediated disorders
IL153605A0 (en) Indole derivatives useful for the treatment of cns disorders
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
AU1028501A (en) Isoquinoline and quinazoline derivatives for the treatment of cns disorders
IL153254A0 (en) Indole derivatives useful for the treatment of cns disorders
ZA995212B (en) The use of aryl-cyclohexylamine derivatives against CNS disorders.
AU6007900A (en) Azetidine carboxamide derivatives for the treatment of cns disorders
HK1059086A1 (en) Indole derivatives useful for the treatment of cns disorders
IL153351A0 (en) Indole derivatives useful for the treatment of cns disorders
SI1305307T1 (en) Indole derivatives useful for the treatment of cns disorders
SI1294710T1 (en) Indole derivatives useful for the treatment of cns disorders